However, CD8+ tumor-infiltrating lymphocytes (TILs) in BRCA1/2 mutant ovarian cancer were found to be more prone to enter a state of depletion, and their reactivation after anti-PD-1 treatment was relatively weak (32). The gene discussed is CD8A; the disease is neoplasm.